{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007139","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.977638+00:00","generated_at":"2026-05-16T02:27:49.813470+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules","bullets":["CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.","Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.","Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.","Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007139","json":"https://secwatch.observer/filing/0001493152-26-007139.json","markdown":"https://secwatch.observer/filing/0001493152-26-007139.md","text":"https://secwatch.observer/filing/0001493152-26-007139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/0001493152-26-007139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:27:49.813470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}